Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$120 Mln
P/E Ratio
--
P/B Ratio
1.2
Industry P/E
--
Debt to Equity
0.19
ROE
-0.43 %
ROCE
-33.27 %
Div. Yield
0 %
Book Value
1.08
EPS
-0.34
CFO
€-302.99 Mln
EBITDA
€-421.80 Mln
Net Profit
€-410.07 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
| -50.19 | -19.02 | -44.30 | -33.67 | 19.94 | -24.97 | -23.49 |
|
BSE Sensex*
| 1.73 | 3.51 | 4.96 | 8.91 | 11.19 | 21.04 | 11.14 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
| -46.49 | -53.81 | 90.71 | -57.62 | -37.20 | 385.09 | -34.18 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 4.24 | 517.80 | 26.63 | 3.8 | |
| 1.14 | 71.16 | -- | -56.15 | |
| 14.50 | 762.90 | -- | -49.94 |
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide... (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as additional programs in Rett Syndrome, additional CNS programs, and multiple other unnamed targets and programs. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. Address: Zernikedreef 9, Leiden, Netherlands, 2333 CK Read more
Founder & Independent Chairman of Supervisory Board
Dr. Domenico Valerio Ph.D.
Founder & Independent Chairman of Supervisory Board
Dr. Domenico Valerio Ph.D.
Headquarters
Leiden
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of ProQR Therapeutics NV - ADR stood at $ 168 Mln as on 31-Dec-24
The share price of ProQR Therapeutics NV - ADR is $1.32 (NASDAQ) as of 21-Apr-2025 16:23 EDT. ProQR Therapeutics NV - ADR has given a return of 19.94% in the last 3 years.
ProQR Therapeutics NV - ADR has a market capitalisation of $ 120 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of ProQR Therapeutics NV - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the ProQR Therapeutics NV - ADR and enter the required number of quantities and click on buy to purchase the shares of ProQR Therapeutics NV - ADR.
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as additional programs in Rett Syndrome, additional CNS programs, and multiple other unnamed targets and programs. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. Address: Zernikedreef 9, Leiden, Netherlands, 2333 CK
The CEO & director of Dr. Domenico Valerio Ph.D.. is ProQR Therapeutics NV - ADR, and CFO & Sr. VP is Dr. Domenico Valerio Ph.D..
There is no promoter pledging in ProQR Therapeutics NV - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
105
|
|
|
91
|
|
|
15
|
|
|
105
|
| ProQR Therapeutics N.V. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-42.73
|
|
Operating margin(%)
|
-142.2
|
|
Net Margin(%)
|
-146.86
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of ProQR Therapeutics NV - ADR was $0 Mln.
$0.18
(
